ReviewFrontiers in immunology2020
Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Laser interstitial thermal therapy (LITT) for brain metastases: a systematic review and pooled analysis of Efficacy/Safety and the role of combination treatments.Journal of neuro-oncology · 2026Pooled it
- The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.Frontiers in oncology · 2022Pooled it
- Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study.Human vaccines & immunotherapeutics · 2026Observational
- Role of hyperthermia in overcoming HPV‑mediated MHC‑Ⅰ downregulation and promoting immune surveillance.International journal of molecular medicine · 2026Article
- Iron-based magnetic nanoplatforms for immune microenvironment remodeling and cancer immunotherapy: progress and prospects.Journal of nanobiotechnology · 2026Review
- Hyperthermia Combined with Anti-CTLA-4 Antibody Induces Tumor Microenvironment Remodeling Involving CD4Cancers · 2026Article
- Targeted hyperthermia therapy (THT) using gold nanorods remodels the tumor microenvironment to sensitize murine microsatellite-stable colorectal cancer to immune checkpoint blockade.Journal of nanobiotechnology · 2026Article
- Thermal modulation enhances antitumour immunity and improves immunotherapy responses in lung cancer.Discover oncology · 2026Review
- Therapeutic exploration of combined local hyperthermia and anti-CD200 blockade therapy in the EMT6 breast cancer model.Medical oncology (Northwood, London, England) · 2026Article
- Antitumor Effects of PD-1 Blockade Combined with Mild Hyperthermia in a Murine Osteosarcoma Model.Biomedicines · 2026Article
- Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents.Frontiers in immunology · 2026Review
- Magnetic Nanoparticles as a Theranostic Platform in Brain Tumor Treatment: Surmounting the Bench-to-Bedside Barriers.International journal of nanomedicine · 2026Review
- An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports.Frontiers in oncology · 2026Article
- Artificial neural network-based immune biomarker signature predicts pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer.Frontiers in oncology · 2026Article
- Mild microwave hyperthermia promotes mitotic catastrophe, induces time-delayed cGAS-STING activation and restores sensitivity to anti-PDL1 therapy in Pan02 pancreatic cancer model.Oncoimmunology · 2025Article
- Impact of mild hyperthermia on tumor-immune dynamics explored through mathematical modeling.Scientific reports · 2025Article
- Emerging photothermal agents combined with immunotherapy for cancer treatment.Discover oncology · 2025Review
- Exploring the Interplay Between Hyperthermia and Cytotoxic Drugs in Ocular Melanoma Cell Lines: Implications and Variability in Treatment Efficiency.Investigative ophthalmology & visual science · 2025Article
- Recent Progress of Nanomedicine for the Synergetic Treatment of Radiotherapy (RT) and Photothermal Treatment (PTT).Cancers · 2025Review
- Hyperthermia-induced cytotoxicity and modulation of PD-L1 and MHC-I expression in human non-small cell lung cancer cell lines.Experimental physiology · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have ushered in a new era of cancer therapy; however, ICIs are only effective in selective patients. The efficacy of ICIs is closely related to the tumor microenvironment. Fever for a long time was thought to directly regulate the immune response, and artificial "fever" from hyperthermia modulates the tumor immune microenvironment by providing danger signals with heat shock proteins (HSPs) as well as subsequent activation of immune systems. Encouraging results have been achieved in preclinical studies focused on potential synergetic effects by combining hyperthermia with ICIs. In this review, we summarized a cluster of immune-related factors that not only make hyperthermia a treatment capable of defending against cancer but also make hyperthermia a reliable treatment that creates a type I-like tumor microenvironment (overexpression of PD-L1 and enrichment of tumor infiltrating lymphocytes) in complementary for the enhancement of the ICIs. Then we reviewed recent preclinical data of the combination regimens involving hyperthermia and ICIs that demonstrated the combined efficacy and illustrated possible approaches to further boost the effectiveness of this combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.